Document:

strm_Ex10_7

		

			Ex

		

		
			Exhibit 10.7
		

		
			 
		

		
			EMPLOYMENT AGREEMENT
		

		
			 
		

		
			This EMPLOYMENT AGREEMENT (together with Exhibit A, the “Agreement”) is entered as of February 18, 2019,  by and between Streamline Health Solutions, Inc., a Delaware corporation with its headquarters in Atlanta, Georgia (the “Company”), and David A. Driscoll, a resident of the state of Virginia (“Executive”).
		

		
			 
		

		
			RECITALS:
		

		
			 
		

		
			WHEREAS, the Company and Executive hereby agree that Executive will serve as an officer of the Company pursuant to the terms and conditions set forth in this Agreement.
		

		
			 
		

		
			NOW, THEREFORE, in consideration of the premises and the agreements contained herein, and for other good and valuable consideration, the receipt and adequacy of which the parties hereby acknowledge, the parties agree as follows:
		

		
			 
		

			
	
			
				 1.
			

			
	
			
			EMPLOYMENT

		
			 
		

		
			The Company hereby agrees to employ Executive, and Executive, in consideration of such employment and other consideration set forth herein, hereby accepts employment, upon the terms and conditions set forth herein.
		

		
			 
		

			
	
			
				 2.
			

			
	
			
			POSITION AND DUTIES

		
			 
		

		
			During the Term (as defined in Section 10 of this Agreement), Executive will be employed as Chief  Revenue Officer of the Company and may also serve as an officer or director of affiliates of the Company for no additional compensation, as part of Executive’s services to the Company hereunder. While employed hereunder, Executive will do all things necessary, legal and incident to the above positions, and otherwise will perform such executive-level functions, as the Chief Executive Officer of the Company (the “CEO”), to whom Executive will report, or the Board of Directors of the Company (the “Board”) may establish from time to time.
		

		
			 
		

			
	
			
				 3.
			

			
	
			
			COMPENSATION AND BENEFITS

		
			 
		

		
			Subject to such modifications as may be contemplated by Exhibit A and approved from time to time by the Board or the Compensation Committee of the Board (the “Committee”), and unless otherwise consented to by Executive, Executive will receive the compensation and benefits listed on the attached Exhibit A, which is incorporated herein and expressly made a part of this Agreement. Such compensation and benefits will be paid and provided by the Company in accordance with the Company’s regular payroll, compensation and benefits policies.
		

		
			 
		

			
	
			
				 4.
			

			
	
			
			EXPENSES

		
			 
		

		
			The Company will pay or reimburse Executive for all travel and out-of-pocket expenses reasonably incurred or paid by  Executive in connection with the performance of Executive’s duties as an employee of the Company upon compliance with the Company’s procedures for expense reimbursement, including the presentation of expense statements or receipts or such other supporting documentation as the Company may reasonably require. All expenses eligible for reimbursements in connection with the Executive’s employment with the Company must be incurred by Executive during the term of employment and must be in accordance with 

		 

		

			37795120 

		

 

		

			Ex

		

the Company’s expense reimbursement policies. The amount of reimbursable expenses incurred in one taxable year will not affect the expenses eligible for reimbursement in any other taxable year. Each category of reimbursement will be paid as soon as administratively practicable, but in no event will any such reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. No right to reimbursement is subject to liquidation or exchange for other benefits.
		

		
			 
		

			
	
			
				 5.
			

			
	
			
			BINDING AGREEMENT

		
			 
		

		
			The Company warrants and represents to Executive that the Company, acting by the officer executing this Agreement on its behalf of the Company, has the full right and authority to enter into this Agreement and to perform all of its obligations hereunder.
		

		
			 
		

			
	
			
				 6.
			

			
	
			
			OUTSIDE EMPLOYMENT

		
			 
		

		
			Executive will devote Executive’s full time and attention to the performance of the duties incident to Executive’s position  with  the Company, and will not have any other employment with any other enterprise or substantial responsibility for any enterprise which would be inconsistent with Executive’s duty to devote Executive’s full time and attention to Company matters; provided, however, that  the foregoing will not prevent Executive from participation in any charitable or civic organization or, subject to CEO consent, which consent will not be unreasonably withheld, from service in a non-executive capacity on the boards of directors of up to two other companies that does not interfere with Executive’s performance of the duties and responsibilities to  be performed by Executive under this Agreement.
		

		
			 
		

			
	
			
				 7.
			

			
	
			
			CONFIDENTIAL INFORMATION AND TRADE SECRETS

		
			 
		

		
			The Company is in the business of providing solutions, including comprehensive suites of health  information management solutions relating to enterprise content management, computer assisted coding, business analytics, clinical analytics and integrated workflow systems, that help hospitals, physician groups and other healthcare organizations improve efficiencies and business processes across the enterprise to enhance and protect revenues, offering a flexible, customizable way to optimize the clinical and financial performance of any healthcare organization (the “Business”). 
		

		
			 
		

		
			For the purpose of this Agreement, “Confidential Information” will mean any written or unwritten information  which  relates to  or is used in the Company’s Business (including, without limitation, the Company’s services, processes, patents, systems, equipment, creations, designs, formats, programming, discoveries, inventions, improvements, computer programs, data kept on computers, engineering, research, development, applications, financial information, information regarding services and products in development, market information, including test marketing or localized marketing, other information regarding processes or plans in  development, trade secrets, training manuals, know-how of the Company, and the customers, clients, suppliers and others with whom the Company does or has in the past done, business (including any information about the identity of the  Company’s  customers  or suppliers and written customer lists and customer prospect lists), or information about customer requirements, transactions, work orders, pricing policies, plans or any other Confidential Information, which the  Company deems confidential and proprietary  and which  is generally  not known to others outside the Company and which  gives or tends to  give the  Company a  competitive  advantage over persons who do not possess such information or the secrecy of which is otherwise of value to the Company in the conduct of its business —  regardless of when and by whom such information was developed or acquired, and regardless  of whether any  of these  are  described in writing, reduced to practice, copyrightable or considered copyrightable, patentable or considered patentable; provided, however, that “Confidential Information” will not include general industry information or information which is publicly available or is otherwise in the public domain without breach of this Agreement, information which Executive has lawfully acquired from a source other than through his employment with the Company, or information which is required to be disclosed pursuant to any law, 

		 

		

			37795120 

		

 

		

			Ex

		

regulation  or rule of any governmental body or authority or court order (in which event Executive will immediately notify the Company of such requirement or order so as to give the Company an opportunity to seek a protective order or other manner of protection prior to production or disclosure of the information). Executive acknowledges that Confidential Information is novel and proprietary to and of considerable value to the Company.
		

		
			 
		

		
			Confidential Information will also include confidential information of third parties, clients or prospective clients that has been provided to the Company or to Executive in conjunction with Executive’s employment, which information the Company is obligated to treat as confidential. Confidential Information does not include information voluntarily disclosed to the public by the Company,  except where such public disclosure has been made by the Executive without authorization from the Company, or which has been independently developed and disclosed by others, or which has otherwise entered the public domain through lawful means.
		

		
			 
		

		
			Executive acknowledges that all Confidential Information is the valuable, unique and special asset of the Company and that the Company owns the sole and exclusive right, title and interest in and to this Confidential Information.
		

		
			 
		

			
	
			
				 (a)
			To the extent that the Confidential Information rises to the level of a trade secret under  applicable law, then Executive will, during Executive’s employment and for as long thereafter as the Confidential Information remains a  trade  secret (or for the maximum period of time otherwise allowed under applicable law) protect and maintain the confidentiality of these trade secrets and refrain from disclosing, copying or using the trade secrets without the Company’s prior written consent, except as necessary in Executive’s performance of Executive’s duties while employed with the Company.

		
			 
		

			
	
			
				 (b)
			To the extent that the Confidential Information defined above does not rise to the level of a trade secret under applicable law, Executive will not, during Executive’s employment and thereafter for a period of two (2) years, disclose, or cause to be disclosed in any way, Confidential Information, or any part thereof, to any person, firm, corporation,  association  or  any  other  operation or entity, or use the Confidential Information on  Executive’s own  behalf, for any  reason  or purpose except as necessary  in the performance of his duties while employed with the Company. Executive further agrees that, during Executive’s employment and thereafter for a period of two (2) years, Executive will not distribute, or cause to be distributed, Confidential Information to any third person or permit the reproduction of Confidential Information, except on behalf of the Company in Executive’s capacity as an employee of the Company. Executive will take all reasonable care to avoid unauthorized disclosure or use of the Confidential Information. Executive agrees that all restrictions contained in this Section 7 are reasonable and valid under the circumstances and hereby waives all defenses to the strict enforcement thereof by the Company.

		
			 
		

		
			Executive agrees that, upon the request of the Company, or in any event immediately upon termination of his employment for whatever reason, Executive will immediately deliver up to the Company or its designee all Confidential Information in Executive’s possession or control, and all notes, records, memoranda, correspondence, files and other papers, and all copies thereof, relating to or containing Confidential Information. Executive does not have, nor can Executive acquire, any property or other rights in Confidential Information.
		

		
			 
		

			
	
			
				 8.
			

			
	
			
			PROPERTY OF THE COMPANY

		
			 
		

		
			All ideas, inventions, discoveries, proprietary information, know-how, processes and other developments  and,  more  specifically, improvements to existing inventions, conceived by Executive, alone or with others, during the term of Executive’s employment with the Company, whether or not during working hours and whether or not while working on a specific project, that are within the scope of the Company’s Business operations or that relate to any work or projects of the Company, are and will remain the exclusive property of the Company. Inventions, improvements and discoveries relating to the Business of the Company conceived or made by Executive, either alone or with others, while employed with the Company are conclusively and irrefutably 

		 

		

			37795120 

		

 

		

			Ex

		

presumed to have been made during the period of employment and are the sole property of the Company.  The Executive will promptly disclose in writing any such matters to the Company but to no other person without the consent of the Company. Executive hereby assigns and agrees to assign all right, title and interest in and to such matters to the Company.  Executive will, upon request of the Company,  execute such assignments or other instruments and assist the Company in the obtaining, at the Company’s sole expense,  of any patents, trademarks or similar protection, if available, in the name of the Company.
		

		
			 
		

			
	
			
				 9.
			

			
	
			
			PROTECTIVE COVENANTS

		
			 
		

			
	
			
				 (a)
			Non-Solicitation of Customers or Clients. During Executive’s employment and for a period of two (2) years following the date of any voluntary or involuntary termination of Executive’s employment for any reason, Executive agrees not to solicit, directly or indirectly (including by assisting others), any business from any of the Company’s customers or clients, including actively sought prospective customers or clients, with whom Executive has had material contact during  Executive’s employment with the Company, for the purpose of providing products or services that are competitive with those provided by the Company. As used in this paragraph, “material contact” means the contact between Executive and each customer, client or vendor, or potential customer, client or vendor (i) with whom or which Executive dealt on behalf of the Company, (ii) whose dealings with the Company were coordinated or supervised  by Executive, (iii) about whom Executive obtained confidential information in the ordinary course of business as a result of Executive’s association  with  the Company, or (iv) who receives products or services authorized by the Company, the sale or provision of which products or services results or resulted in compensation, commissions or earnings for Executive within two years prior to the date of the Executive’s termination.

		
			 
		

			
	
			
				 (b)
			Non-Piracy of Employees.  During Executive’s employment and for a period of two (2) years following the date of any voluntary or involuntary termination of Executive’s employment for any reason, Executive  covenants and  agrees that Executive  will not, directly or indirectly, within the Territory, as defined below: (i) solicit, recruit or hire (or attempt to solicit, recruit or hire) or otherwise assist anyone in soliciting, recruiting or hiring, any employee or independent contractor of the Company who performed work for the Company and worked with Executive within the last year of Executive’s employment with the Company, or (ii) otherwise encourage, solicit or support any such employee or independent contractor to leave his or her employment or engagement with the Company.

		
			 
		

			
	
			
				 (c)
			Non-Compete.  During Executive’s employment with the Company and (i) for a period of two (2) years following the date of any termination  of Executive’s employment for any reason other than termination of Executive’s employment by the Company without Good Cause or by the Executive for Good Reason or (ii) for a period of one (1) year following the date of any termination of Executive’s employment with the Company by the Company without Good Cause or by the Executive for Good Reason; and provided in each of (i) and (ii) that the  Company is not in  default  of its obligations specified in Sections 11 and 13 hereof, Executive agrees not to, directly or indirectly, compete with the Company, as an officer, director, member, principal, partner, shareholder, owner, manager, supervisor, administrator, employee, consultant or independent contractor, by working for a competitor to, or engaging in competition with, the Business, in the Territory, in a capacity in which Executive performs duties and responsibilities that are the same as or similar to the duties performed by Executive while employed by the Company, provided that the foregoing will not prohibit Executive from owning not more than 5% of the outstanding stock of a corporation subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The “Territory” will be defined to be that geographic area comprised of the following states in the United States of America, the District of Columbia, the Canadian provinces of Quebec and Alberta:

		
			 
		

		

		 

		

			37795120 

		

 

		

			Ex

		

	
					
						

					
						Alabama

					
					
						Indiana

					
					
						Nebraska

					
					
						South Carolina

				
	
					
						Alaska

					
					
						Iowa

					
					
						Nevada

					
					
						South Dakota

				
	
					
						Arizona

					
					
						Kansas

					
					
						New Hampshire

					
					
						Tennessee

				
	
					
						Arkansas

					
					
						Kentucky

					
					
						New Jersey

					
					
						Texas

				
	
					
						California

					
					
						Louisiana

					
					
						New Mexico

					
					
						Utah

				
	
					
						Colorado

					
					
						Maine

					
					
						New York

					
					
						Vermont

				
	
					
						Connecticut Delaware

					
					
						Maryland

					
					
						North Carolina

					
					
						Virginia

				
	
					
						Florida

					
					
						Massachusetts

					
					
						North Dakota

					
					
						Washington

				
	
					
						Georgia

					
					
						Michigan

					
					
						Ohio

					
					
						West Virginia

				
	
					
						Hawaii

					
					
						Minnesota

					
					
						Oklahoma

					
					
						Wisconsin

				
	
					
						Idaho

					
					
						Mississippi

					
					
						Oregon

					
					
						Wyoming

				
	
					
						Illinois

					
					
						Missouri

					
					
						Pennsylvania

					
					
						 

				
	
					
						 

					
					
						Montana

					
					
						Rhode Island

					
					
						 

				

		
			 
		

		
			; provided, however, that the Territory described herein is a good faith  estimate  of the  geographic area  that is now applicable as the area in which the Company does or will do business during the term of Executive’s employment, and the  Company and Executive  agree that this non-compete covenant will ultimately be construed to cover only so much of such Territory  as  relates  to  the  geographic areas in which the Executive does business for and on behalf of the Company within the two-year period preceding termination of Executive’s employment.
		

		
			 
		

			
	
			
				 10.
			

			
	
			
			TERM

		
			 
		

		
			Unless earlier terminated pursuant to Section 11 herein, the term of this Agreement will be for a period beginning on the start date specified in Exhibit A and ending on February [18], 2020 (the “Initial Term”). Upon expiration of the Initial Term, this Agreement will automatically renew in successive one-year periods (each a  “Renewal Period”), unless Executive or the Company notifies the other party at least 60 days prior to the end of the Initial Term or the applicable Renewal Period that this Agreement will not be renewed. The Initial Term, and, if this Agreement is renewed in accordance with this Section 10, each Renewal Period, will be included in the definition of “Term” for purposes of this Agreement. Unless waived in writing by the Company, the requirements of Section 7 (Confidential Information and Trade Secrets), Section 8 (Property of the Company) and Section 9 (Protective Covenants)  will survive the expiration or termination of this Agreement or Executive’s employment for any reason.
		

		
			 
		

			
	
			
				 11.
			

			
	
			
			TERMINATION

		
			 
		

			
	
			
				 (a)
			Death.  This Agreement and Executive’s employment hereunder will be terminated on the death of Executive, effective as of the date of Executive’s death. In such event, the Company will pay to  the estate of Executive the sum of (i) accrued but unpaid  base salary earned prior to Executive’s death (to be paid in accordance with normal practices of the Company) and (ii) expenses incurred by Executive prior to his death for which Executive is entitled to reimbursement under (and paid in accordance with) Section 4 herein, and Executive will be entitled to no severance or other post-termination benefits.

		
			 
		

			
	
			
				 (b)
			Continued Disability. This Agreement and Executive’s employment hereunder may be terminated, at the option of the Company, upon a  Continued Disability (as defined herein) of Executive. For the purposes of this Agreement, and unless otherwise required under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), “Continued Disability” will be defined as the inability or incapacity (either mental or physical) of Executive to continue to perform Executive’s duties hereunder for a continuous period of one hundred twenty (120) working days, or if, during any calendar year of the Term  hereof because of  disability, Executive will have been unable to perform Executive’s duties hereunder for a total period of one hundred eighty (180) working days regardless of whether or not such days are consecutive. The determination as to whether 

		 

		

			37795120 

		

 

		

			Ex

		

	Executive is unable to perform the essential functions of Executive’s job will be made by the Board or the Committee in its reasonable discretion; provided, however, that if Executive is not satisfied with the decision of the Board or the Committee, Executive will submit to examination by three competent physicians who practice in the metropolitan area in which the  Company maintains its principal executive office, one of whom will be selected by the Company, another of whom will be selected by Executive, with the third  to  be  selected  by  the physicians so selected. The determination of a majority of the physicians so selected will supersede the determination of the Board or the Committee and will be final and conclusive. In the event of the termination of Executive’s employment  due  to  Continued Disability, the Company will pay to Executive the sum of (i) accrued but unpaid base salary earned prior  to  the  date  of  the Executive’s termination of employment due to Continued Disability (paid in  accordance with  the normal practices of the Company), and (ii) expenses incurred by Executive prior to his termination of employment for which Executive is  entitled  to  reimbursement  under (and paid in accordance with) Section 4 herein, and Executive will be entitled to no  severance  or  other  post-termination benefits.

		
			 
		

			
	
			
				 (c)
			Termination by the Company for Good Cause, by Executive Other Than for Good Reason, or upon Non-Renewal of the Term by Executive.  Notwithstanding any other provision of this Agreement, the Company may at any time terminate this Agreement and Executive’s employment hereunder for Good Cause, Executive may at any time terminate his employment other than for Good Reason (as defined in Section 11(d) herein), or Executive may notify the Company that he will not renew the Term. For this purpose, “Good Cause” will include the following: the current use of illegal drugs; conviction of any  crime  which  involves  moral turpitude, fraud or misrepresentation; commission of any act which would constitute a felony or which adversely impacts  the  business  or reputation of the Company; fraud; misappropriation or embezzlement of Company funds or property; willful misconduct or grossly negligent or reckless conduct which is materially injurious to the reputation, business or business relationships  of  the  Company; material violation or default on any of the provisions of this Agreement; or material and continuous failure to meet reasonable performance criteria or reasonable standards of conduct as established from time to time by the Board, which  failure continues for at  least 30 days after written notice from the Company to Executive. Notice of a termination by the Company for Good Cause will be delivered in writing to Executive stating the Good Cause for such action. If the employment of Executive is terminated by the Company for Good Cause, if Executive terminates employment for any reason other than for Good Reason (including, but not limited to, resignation), or if Executive notifies the Company he will not renew the Term, then, the Company will pay to Executive the sum of (i) accrued but unpaid salary through the termination date (paid in accordance with the normal practices of the Company), and (ii) expenses incurred by Executive prior to his termination date for which Executive is entitled to reimbursement under (and paid in accordance with) Section 4 herein, and Executive will be entitled to no severance or other post- termination benefits.

		
			 
		

			
	
			
				 (d)
			Termination by the Company without Good Cause or by Executive for Good Reason.  The Company may terminate this Agreement and Executive’s employment at any time, including for reasons other than Good Cause (as “Good Cause” is defined in Section 11(c) above), Executive may terminate his employment at any time, including for Good Reason, or the Company may elect not to renew the Term. For the purposes herein, “Good Reason” will mean (i) a material diminution of Executive’s base salary; (ii) a material diminution in Executive’s authority, duties, or responsibilities; or (iii) any other action or inaction that constitutes a material breach of the terms of this Agreement; provided that Executive’s termination will not be treated as for Good Reason unless Executive provides the Company with notice of the existence of the condition claimed to constitute Good Reason within 45 days of the initial existence of such condition and the Company fails to remedy such condition within 30 days following the Company’s receipt of such notice. In the event that (i) the Company terminates the employment of Executive  during  the  Term  for  reasons other than  for Good Cause, death or Continued Disability or (ii) Executive terminates employment for Good Reason, then the Company will pay Executive the sum of (A) accrued but unpaid salary through the termination date, and payments of any bonuses and commission earned and payable for up to 90 days following the termination date (as paid in accordance with the normal practices of the Company), (B) expenses incurred by Executive prior to his termination date for which Executive  is entitled  to  reimbursement under  (and paid in accordance with) Section  4  herein, and (C) provided that Executive is not in  default of his obligations under Section  7, 8, or 9  herein, an amount equal to six months’ 

		 

		

			37795120 

		

 

		

			Ex

		

	base salary ((A) through (C), being hereinafter referred to, collectively, as the “Separation Benefits”). In such event, the payments described in (C) in  the preceding sentence will be made following  Executive’s execution (and non-revocation) of a form of general release of claims as  is acceptable to the Board or the Committee if the general release form is provided to the Executive  within  one  month  of  the Executive’s date of termination, in accordance with the normal payroll practices of the Company; provided that the portion of the severance payment described in clause (C) above that exceeds the “separation pay limit,” if any, will be paid to  the  Executive  in  a  lump sum payment within thirty (30) days following the date of Executive’s termination of employment (or such earlier date following  the date of Executive’s termination of employment, if any, as may be required under applicable wage payment laws), but in  no event later than the fifteenth (15th)  day of the third (3rd) month following the Executive’s date of termination. The “separation pay limit” will mean two (2) times the lesser of: (1) the sum of Executive's annualized compensation based upon the annual rate of pay for services provided to the Company for the calendar year immediately preceding the calendar year in which Executive's date of termination of employment occurs (adjusted for any increase during that calendar year that was expected to continue indefinitely if Executive had not terminated employment); and (2) the maximum dollar amount of compensation that may be taken into account under a tax-qualified retirement plan under Code Section 401(a)(17) for the year in which his termination of employment occurs. The lump-sum payment to   be made to Executive pursuant to this Section 11(d) is intended to be exempt from Code Section 409A under the exemption found in Regulation Section 1.409A-1(b)(4) for short-term deferrals. The remaining portion of the severance payment described in clause (C) above will be paid in periodic installments over the 15-month period commencing on the first post-termination payroll date following expiration of the revocation period described above and will be paid in accordance with the normal payroll practices of the Company. Notwithstanding the foregoing, in no event will such remaining portion of the severance payment described in clause (C) above be paid to Executive later than December 31 of the second calendar year following the calendar year in which Executive's date of termination of employment occurs. The payments to be made to Executive pursuant to the immediately preceding sentence are intended to be exempt from Code Section 409A under the exemption found in Regulation Section 1.409A-1(b)(9)(iii) for separation pay plans (i.e., the so-called “two times” pay exemption). For the sake of clarity, no election by the Company not to renew the Term will trigger any rights to severance or other benefits.

		
			 
		

			
	
			
				 (e)
			Payment of COBRA Premiums.  In the event that the Company terminates Executive’s employment for any reason  other than Good Cause or Executive terminates his employment for Good Reason, then, provided that Executive timely elects to receive continued coverage under the Company’s group medical and dental insurance plans pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended (“COBRA”), for the period commencing on the  date  of  Executive’s  termination  and continuing until the earlier of the end of the six-month period following his termination date or the first of the month immediately following the Company’s receipt of notice from  Executive  terminating  such coverage, Executive  (and any qualified  dependents) will  be entitled to coverage under such plans (as may be amended during the period of coverage) in which Executive was participating immediately prior to the date of his termination of employment (the “COBRA Coverage”). The cost of the premiums for such coverage will be borne by the Company, except that Executive will reimburse the Company for premiums becoming due each month with respect to such coverage in an amount equal to the difference between the amount of such premiums and the portion thereof currently being paid by Executive. Executive’s portion of such premiums will be payable by the first of each month commencing the first month following the month in which his termination of employment occurs. The period during which Executive is being provided with health insurance under this Agreement at the Company’s expense will be credited against Executive’s period of COBRA coverage, if any. Further, if at any time during the period Executive is entitled to premium payments under this Section 11(e), Executive becomes entitled to receive health insurance from a subsequent employer, the Company’s obligation to continue premium payments to Executive shall terminate immediately.

		
			 
		

			
	
			
				 12.
			

			
	
			
			ADVICE TO PROSPECTIVE EMPLOYERS

		
			 
		

		
			

		 

		

			37795120 

		

 

		

			Ex

		

		

		
			If Executive seeks or is offered employment by any other company, firm or person during his employment or during the post- termination restricted periods, he will notify the prospective employer of the existence and terms of the non-competition and confidentiality agreements set forth in Sections 7 and 9  of this Agreement. Executive may disclose the language of Sections 7 and 9 but may not disclose the remainder of this Agreement.
		

		
			 
		

			
	
			
				 13.
			

			
	
			
			CHANGE IN CONTROL

		
			 
		

			
	
			
				 (a)
			In the event of a  Change in Control (as defined herein) of the Company, (i) all stock options, restricted stock, and all other equity awards granted to Executive prior to the Change in Control will immediately vest in full, (ii) if, within 90 days prior to a Change in Control, the Company terminates the employment of Executive for reasons other than for Good Cause, death or Continued Disability, or Executive terminates employment for Good Reason, then, the Company will (x) pay the Executive the sum of (A) accrued but unpaid salary through the termination date (paid in accordance with the normal practices of the Company), (B) expenses incurred by Executive prior to his termination date for which Executive is entitled to reimbursement under (and paid in accordance with) Section 4 herein, and (C) provided that Executive is not in default of his obligations under Section 7, 8, or 9  herein, an amount equal to twelve months’ base salary ((A) through (C), being hereinafter referred to, collectively, as the “Change in Control Separation Benefits”) and (y) provide the COBRA Coverage, and all other stock options, restricted stock, and other equity awards granted to Executive will immediately vest in full as of the date of termination and will remain exercisable until the earlier of the end of the applicable option period or one hundred and eighty (180) days from the date of Executive’s termination of employment, and (iii) if, within 12 months following a Change in Control, the Company terminates the employment of Executive for reasons other than for Good Cause, death or Continued Disability or Executive terminates employment for Good Reason, then (a) the Company will provide the Change in Control Separation  Benefits and the  COBRA Coverage, and (b) all stock options, restricted stock, and other equity awards granted to Executive will immediately vest in full as of the date of termination and will remain exercisable until the earlier of the end of the applicable option period or one hundred and eighty (180) days from the date of Executive’s termination of employment. In the event Executive seeks to terminate his employment for Good Reason, such termination will not be treated for purposes of this Section 13 as a termination for Good Reason unless Executive provides the Company with notice of the existence of the condition claimed to constitute Good Reason within 90 days of the initial existence of such condition and the Company fails to remedy such condition within 30 days following the Company’s receipt of such notice.

		
			 
		

			
	
			
				 (b)
			For purposes of this Agreement, “Change in Control” means any of the following events:

		
			 
		

			
	
			
				 (i)
			A  change in control of the direction and administration of the Company’s business of a  nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A promulgated under the Exchange Act, as in effect on the date hereof and any successor provision of the regulations under the Exchange Act, whether or not the Company is then subject to such reporting requirements; or

		
			 
		

			
	
			
				 (ii)
			Any “person” (as such term is used in Section 13(d) and Section 14(d)(2) of the Exchange Act but excluding any employee benefit plan of the Company) is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than one half of the combined voting power of the Company’s outstanding securities then entitled to vote for the election of directors; or

		
			 
		

			
	
			
				 (iii)
			The Company sells all or substantially all of the assets of the Company; or

		
			 
		

			
	
			
				 (iv)
			The consummation of a merger, reorganization, consolidation or similar business combination that constitutes a change in control as defined in the Company’s 2013 Second Amended and 

		 

		

			37795120 

		

 

		

			Ex

		

	Restated Stock Incentive Plan or other successor stock plan or results in the occurrence of any event described in Sections 13(b) (i), (ii) or (iii) above.

		
			 
		

			
	
			
				 (c)
			Notwithstanding anything to the contrary contained in this Agreement, in  the event any amounts payable hereunder would be considered to be excess parachute payments for purposes of the amount payable following the occurrence of a  Change of Control  that is treated as a “change in the ownership or effective control” of the Company or “in the ownership of a substantial portion of the assets” of the Company for purposes of Code Sections 280G and 4999, those payments that are treated for purposes of Code Section 280G as being contingent on a  “change in the ownership or effective control”  (as that phrase is used for purposes of Code Section  280G) of the Company will be reduced, if and to the extent necessary, so that no payments under this Agreement are treated as excess parachute payments.

		
			 
		

			
	
			
				 14.
			

			
	
			
			ACKNOWLEDGEMENTS

		
			 
		

		
			The Company and Executive each hereby acknowledge and agree as follows:
		

		
			 
		

			
	
			
				 (a)
			The covenants, restrictions, agreements and obligations set forth herein are founded upon valuable consideration, and, with respect to the covenants, restrictions, agreements and obligations set forth in Sections 7, 8  and 9 hereof, are reasonable in duration, the activities proscribed, and geographic scope;

		
			 
		

			
	
			
				 (b)
			In the event of a  breach or threatened breach by Executive of any of the covenants, restrictions, agreements and obligations set forth in Sections 7, 8  or 9  hereof, monetary damages or the other remedies at law that may be available to  the Company for such breach or threatened breach will be inadequate and, without prejudice to the Company’s right to pursue any other remedies at law or in equity available to it for such breach or threatened breach, including, without limitation, the recovery of damages from Executive, the Company will be entitled to injunctive relief from a court of competent jurisdiction or the arbitrator; and

		
			 
		

			
	
			
				 (c)
			The time period, proscribed activities, and geographical area set forth in Section 9 hereof are each divisible and separable, and, in the event that the covenants not to compete contained therein are judicially held invalid  or unenforceable  as  to  such  time period, scope of activities, or geographical area, they will be valid and enforceable to such extent and in such geographical area(s) and for such time period(s) which the court determines to be reasonable and enforceable. Executive agrees that in the event any court of competent jurisdiction determines that the above covenants are invalid or unenforceable to join with the Company in requesting that court to construe the applicable provision by limiting or reducing it so as to be enforceable to the extent compatible with the then applicable law. Furthermore, any period of restriction or covenant herein stated will not include any period of violation or period of time required for litigation to enforce such restriction or covenant.

		
			 
		

			
	
			
				 15.
			

			
	
			
			NOTICES

		
			 
		

		
			Any notice or communication required or permitted hereunder will be given in writing and will be sufficiently given if delivered personally or sent by telecopy to such party addressed as follows:
		

			
	
			
				 (a)
			

			
	
			
			In the case of the Company, if addressed to it as follows: 

		
			Streamline Health Solutions, Inc. 
		

		
			1175 Peachtree Street NE
		

		
			10th Floor
		

		
			Atlanta, Georgia 30361
		

		
			Attn: Chief Executive Officer
		

		
			 
		

		
			

		 

		

			37795120 

		

 

		

			Ex

		

		

			
	
			
				 (b)
			In the case of Executive, if addressed to Executive at the most recent address on file with the Company.

		
			 
		

		
			Any such notice delivered personally will be deemed to have been received on the date of such delivery. Any address for the giving of notice hereunder may be changed by notice in writing.
		

		
			 
		

			
	
			
				 16.
			

			
	
			
			ASSIGNMENT, SUCCESSORS AND ASSIGNS

		
			 
		

		
			This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective legal representatives, successors and assigns. The Company may assign or otherwise transfer its rights under this Agreement to any successor or affiliated business or corporation (whether by sale of stock, merger, consolidation, sale of assets or otherwise), but this Agreement may not be assigned, nor may his duties hereunder be delegated, by Executive. In the event that the Company assigns or otherwise transfers its rights under this Agreement to any successor or affiliated business or corporation (whether by sale of stock, merger, consolidation, sale of assets or otherwise), for all purposes of this Agreement, the “Company” will then be deemed to include the successor or affiliated business or corporation to which the Company, assigned or otherwise transferred its rights hereunder.
		

		
			 
		

			
	
			
				 17.
			

			
	
			
			MODIFICATION

		
			 
		

		
			This Agreement may not be released, discharged, abandoned, changed or modified in any manner, except by an instrument in writing signed by each of the parties hereto.
		

		
			 
		

			
	
			
				 18.
			

			
	
			
			SEVERABILITY

		
			 
		

		
			The invalidity or unenforceability of any particular provision of this Agreement will not affect any other provisions hereof, and the parties will use their best efforts to substitute a valid, legal and enforceable provision, which, insofar as practical, implements the purpose of this Agreement. If the parties are unable to reach such agreement, then the provisions will be modified as set forth in Section 14(c) above. Any failure to enforce any provision of this Agreement will not constitute a waiver thereof or of any other provision hereof.
		

		
			 
		

			
	
			
				 19.
			

			
	
			
			COUNTERPARTS

		
			 
		

		
			This Agreement may be signed in counterparts (and delivered via facsimile transmission or by digitally scanned signature delivered electronically), and each of such counterparts will constitute an original document and such counterparts, taken together, will constitute one and the same instrument.
		

		
			 
		

			
	
			
				 20.
			

			
	
			
			ENTIRE AGREEMENT

		
			 
		

		
			This constitutes the entire agreement among the parties with respect to the subject matter of this Agreement and supersedes all prior and contemporaneous agreements, understandings, and negotiations, whether written or oral, with respect to such subject matter.
		

		
			 
		

			
	
			
				 21.
			

			
	
			
			DISPUTE RESOLUTION

		
			 
		

		
			Except as set forth in Section 14 above, any and all disputes arising out of or in connection with the execution, interpretation, performance or non-performance of this Agreement or any agreement or other instrument between, involving or affecting the parties (including the validity, scope and enforceability of this arbitration clause), will be submitted to and resolved by arbitration.  The arbitration will be conducted pursuant to the terms of the Federal Arbitration Act and the Employment Arbitration Rules and Mediation Procedures of 

		 

		

			37795120 

		

 

		

			Ex

		

the American Arbitration Association. Either party may notify the other party at any time of the existence of  a controversy potentially requiring arbitration by certified mail, and the parties will attempt in good faith to resolve their differences within fifteen (15) days after the receipt of such notice. If the dispute cannot be resolved within the fifteen-day period, either party may file a written demand for arbitration with the American Arbitration Association. The place of arbitration will be mutually agreed by the parties.
		

		
			 
		

		
			/s/ DD/s/ DS
		

		
			 
		

		
			                     Initialed by ExecutiveInitialed by the Company
		

		
			 
		

			
	
			
				 22.
			

			
	
			
			GOVERNING LAW; FORUM SELECTION

		
			 
		

		
			The provisions of this Agreement will be governed by and interpreted in accordance with the internal laws of the State of Georgia and the laws of the United States applicable therein. Executive acknowledges and agrees that Executive is subject to personal jurisdiction in state and federal courts in Fulton County, Georgia, and waives any objection thereto.
		

		
			 
		

			
	
			
				 23.
			

			
	
			
			CODE SECTION 409A

		
			 
		

		
			Notwithstanding any other provision in this Agreement to  the  contrary, if and to  the  extent that Code Section  409A is deemed to apply to any benefit under this Agreement, it is the general intention of the Company that such  benefits  will,  to  the  extent practicable, comply with, or be exempt from, Code Section 409A, and this Agreement will, to the extent practicable, be construed in accordance therewith. Deferrals of benefits distributable pursuant to this Agreement that are otherwise exempt from Code Section 409A  in a manner that would cause Code Section 409A to apply will not be permitted unless such deferrals follow Code Section 409A. In the event that the Company (or a successor thereto) has any stock which is publicly traded on an established securities market or otherwise and Executive is determined to be a “specified employee” (as defined under Code Section 409A), any payment that is deemed to be deferred compensation under Code Section 409A to be made to the Executive upon a separation from service may not be made before the date that is six months after Executive’s separation from service (or death, if earlier). To the extent  that Executive becomes subject to the six-month delay rule, all payments that would have been made to Executive  during  the  six  months following his separation from service that are not otherwise exempt from Code Section 409A, if any, will be accumulated and paid to Executive during the seventh month following his separation from  service, and any remaining  payments due will be made in  their ordinary course as described in this Agreement. For the purposes herein, the phrase “termination of employment” or similar phrases will be interpreted in accordance with the term “separation from service” as defined under Code Section 409A if and to the extent required under Code Section 409A. Further, (i) in the event that Code Section 409A  requires that any special terms, provisions or conditions be included in this Agreement, then such terms, provisions and conditions will, to the extent practicable, be deemed to be made a  part of this Agreement, and (ii) terms used in this Agreement will be construed in accordance with Code Section 409A if and to the extent required. Further, in the event that this Agreement or any benefit thereunder will be deemed not to comply with Code Section 409A, then neither the Company, the Board, the Committee nor its or their designees or agents will be liable to any participant or other person for actions, decisions or determinations made in good faith.
		

		
			 
		

			
	
			
				 24.
			

			
	
			
			WITHHOLDING.

		
			 
		

		
			The Company may withhold from any amounts payable under this Agreement such federal, state, local or foreign taxes as will be required to be withheld pursuant to any applicable law or regulation.
		

		
			 
		

		
			 
		

		
			[Signature page follows.]
		

		
			 
		

		
			 

		

		
			IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto effective as of the date first above written.
		

		
			 
		

		
			 
		

		
			STREAMLINE HEALTH SOLUTIONS, INC.

		

		
			By: /s/ David Sides2/18/2019
		

		
			David W. Sides
     President and Chief Executive Officer
		

		
			 
		

		
			EXECUTIVE 

		

		
			By: /s/ David Driscoll2/18/2019
		

		
			David A. Driscoll
		

		
			 
		

		
			 
		

		
			

		 

		

			37795120 

		

 

		

			 

		

		

		
			EXHIBIT A TO EMPLOYMENT AGREEMENT (“AGREEMENT”) DATED AS OF FEBRUARY [18], 2019, BETWEEN STREAMLINE HEALTH SOLUTIONS, INC. AND DAVID A. DRISCOLL -- COMPENSATION AND BENEFITS
		

		
			 
		

			
	
			
				 1.
			Start Date. Executive’s start date will be February 18, 2019.

		
			 
		

			
	
			
				 2.
			

			
	
			
			Base Salary. Base Salary will be paid at an annualized rate of $250,000, which will be subject to annual review and adjustment by the Compensation Committee or the Board but will not be reduced below $250,000 without the consent of Executive. Such amounts will be payable to Executive in accordance with the normal payroll practices of the Company.

		
			 
		

			
	
			
				 3.
			

			
	
			
			Annual Bonus.  Target annual bonus and target goals will be set by the Compensation Committee annually and based on a  combination of individual and Company performance. Target annual bonus (prorated for any partial period) will be $100,000.00.  The annual bonus will be paid pursuant to such conditions as are established by the Compensation Committee and, to the extent payable under a bonus plan, subject to such terms and conditions as may be set out in such plan. The annual bonus will, if payable, be paid in cash no later than March 14 of the fiscal year following the fiscal year during which Executive’s right to the annual bonus vests.

		
			 
		

			
	
			
				 4.
			

			
	
			
			Benefits.  Executive will be eligible to participate in the Company’s benefit plans on the same terms and conditions as provided for other Company executives, subject to all terms and conditions of such plans as they may be amended from time to time and will accrue vacation days and personal days totaling an aggregate of 20 days per annum prorated for 2019. 

		
			 
		

			
	
			
				 5.
			Grant of Restricted Stock.  Executive will receive the following grants of equity incentives:

		
			 
		

			
	
			
				 (a)
			

			
	
			
			An inducement grant of 75,000 restricted shares of common stock, par value $0.01 per share, upon your hire date referred to in paragraph 1 above. The vesting of such shares will be in three substantially equal annual installments over the first three years of employment. Such grant will be made pursuant to and otherwise subject to the terms and conditions of the Company’s Second Amended and Restated 2013 Stock Incentive Plan and the related restricted stock grant agreement.   

		
			 
		

			
	
			
				 6.
			

			
	
			
			Management Override.  Executive will be eligible for a management override of 1.5% on all sales made by the Company on an Annual Contract Value basis that will paid consistent with the Company’s annual Regional Vice President of Sales team incentive as updated from time-to-time. 

		
			 
		

		
			 
		

		 

		

			37795120Exhibit 10.11

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT
AGREEMENT (the “Agreement”) is made and entered into this 25th day of March, 2019 (the “Effective Date”),
by and between Todos Medical Ltd., an Israeli company with an address at 1 HaMada Street, Rehovot (the “Company”)
and Dr. Herman Weiss, with an address at 11 Rechov Asher, Bet Shemesh (the “Employee”).

 

WHEREAS, the
Employee has been serving as the Company’s Chief Executive Officer since August 1, 2018 (the “Commencement Date”);

 

WHEREAS, the
Company and the Employee wish to state the terms and conditions of the Employee’s employment with the Company; and

 

WHEREAS, the Company
and the Employee acknowledge that this Agreement is subject to shareholder approval;

 

NOW, THEREFORE,
in consideration of the mutual premises, covenants and other agreements contained herein, the parties hereby agree as follows:

 

		1.	Position.

 

The Employee
shall be employed by the Company as the Company’s Chief Executive Officer. In such position,
the Employee shall report and be subject to the direction and control of the Company’s Board of Directors. The Employee shall perform
his duties diligently, conscientiously and in furtherance of the Company’s best interests. The Employee agrees and undertakes to
inform the Company immediately after becoming aware of any matter that may in any way raise a conflict of interest between the
Employee and the Company. During his employment by the Company, the Employee shall not receive any payment, compensation, or benefit
from any third party in connection with his employment with the Company.

 

		2.	Full-Time Employment.

 

2.1 The
Employee will be employed on a full-time basis. The Employee shall devote his business time and attention to the business of the
Company and shall not undertake or accept any other paid or unpaid employment or occupation or engage in any other business activity
that impairs the Employee’s ability to perform his duties hereunder or that are competitive with the activities of the Company.
The Employee confirms and declares that his position is one that requires a special measure of personal trust and loyalty; accordingly,
the provisions of the Hours of Work and Rest Law-1951 shall not apply to him, and he shall not be entitled to any compensation
other than the compensation set forth in this Agreement for working more than the maximum number of hours per week set forth in
said law or any other applicable law

 

2.2 Notwithstanding
the foregoing, the Employee shall be permitted to pursue other voluntary, professional and/or academic activities, provided that
they do not impair the Employee’s ability to perform his duties hereunder and are not competitive with the activities of the Company.

 

     

     

    

 

		3.	Location.

 

The Employee
shall perform his duties hereunder primarily at the Company’s facilities in Israel, but he understands and agrees that his position
may involve domestic and international travel.

 

		4.	Term.

 

4.1Commencement
Date.The Company and the Employee acknowledge that the Employee’s employment by the Company commenced on the Commencement
Date.

 

4.2At-Will
Relationship.The Employee’s employment by the Company is an “at will” relationship, and may be terminated by
either party at any time in accordance with Section 4.3 below.

 

4.3Notice
Period.Either party may terminate the employment relationship hereunder at any time by giving the other party a prior written
notice as set forth in Exhibit A (the “Notice Period”); provided, however, that termination by
the Company of the Employee’s employment not for cause shall require a Board of Directors resolution. During the Notice Period,
the Employee shall be paid his full salary and benefits, and shall be entitled to all other employment allowances.

 

4.4 End
of Relations. During the Notice Period and unless otherwise determined by the Company in a written notice to the Employee,
the employment relationship hereunder shall remain in full force and effect. The Employee shall be obligated to continue to discharge
and perform all of his duties and obligations with Company, and the Employee shall cooperate with the Company and assist the Company
with the integration into the Company of the person who will assume the Employee’s responsibilities.

 

4.5Severance
Payment.In addition to the amounts of severance due to the Employee pursuant to Israeli law and Section 9 below, in the
event of termination of employment for any reason, the Company shall pay the Employee a severance payment in an amount equal to
six (6) months’ salary; provided, however, that in the event of termination of employment due to a change in control of the
Company (as such term is defined under the Israeli securities law), the Company will pay the Employee a severance payment in an
amount equal to twelve (12) months’ salary (instead of 6 months’ salary) following the effective date of termination.

 

		5.	Termination for Cause

 

The Company
may immediately terminate the employment relationship for Cause, and such termination shall become effective immediately upon delivery
of written notice of the same. “Cause” shall mean (i) a breach by the Employee of the provisions of the Confidentiality,
Invention Assignment, and Non-Competition Agreement (attached as Exhibit B); or (ii) the Employee’s willful misconduct,
or action of personal dishonesty, bad faith, or breach of trust towards the Company; or (iii) the conviction of the Employee of
a criminal offense involving moral turpitude or fraud against the Company.

 

		6.	Confidentiality, Invention Assignment, and Non-Competition.

 

The Employee
shall execute the Confidentiality, Invention Assignment, and Non-Competition Agreement attached hereto as Exhibit B.

 

    2

     

    

 

		7.	Compensation.

 

7.1 Salary.
Retroactive to the Commencement Date, the Company shall pay to the Employee as compensation for the employment services an aggregate
base salary in the amount set forth in Exhibit A (the “Salary”). In addition, in the event the Employee
does not opt to receive a Company car, then the Company shall pay the Employee for any and all daily travel costs to which he may
be entitled under any applicable law, collective bargaining agreements or orders, to the extent any apply. The Employee’s Salary
and other terms of employment shall be reviewed annually and may be updated by the Company’s management, from time to time, at
the Company’s discretion. The Salary is to be paid to the Employee no later than the 7th day of each calendar month
immediately following the month for which the Salary is paid, after deduction of applicable taxes and like payments.

 

7.2Performance
Bonus.The Employee shall be entitled to an annual performance bonus of up to 35% of his annual Salary and up to 1% additional
stock options (based on the number of issued and outstanding shares as of the Effective Date), linked to the achievement of performance
goals to be established by the Board of Directors at the beginning of each calendar year.

 

7.3 Withholdings.
Withholdings shall be deducted at source from payments made hereunder to the Employee according to applicable law, including, but
not limited to, Israeli income tax, National Insurance (“Bituach Leumi”) and Health Tax (“Mas Briut”).
The Employee shall bear any tax imposed in connection with the payments and benefits provided for in this Agreement.

 

		8.	Expenses.

 

The Company
shall pay or reimburse the Employee for all reasonable expenses actually incurred or paid by the Employee in the performance of
his duties hereunder after presentation of expense statements or vouchers and such other supporting information and documentation
as the Company may customarily require of its executive officers.

 

		9.	Managers Insurance and Social Benefits.

 

9.1 The
Company shall provide and maintain a managers insurance policy on behalf of the Employee which will be funded by the amounts mandated
by law to be paid by the employer and all employee contributions. The Company will contribute an amount equal to 8.33% of the Salary
towards severance pay (the “Severance Fund”). In addition, the Company will contribute an amount each month
towards a savings/pension fund (the type of fund will be as per the Employee’s choosing) in accordance with applicable law, subject
to the Employee’s monthly contribution from the Salary (the “Savings Fund”).  The Company will also contribute
an amount of up to 2.5% of the Salary towards disability insurance based on the agreements that the Company has with its benefit
plan vendor.

 

9.2 Additionally,
the Company together with the Employee will maintain an advanced study fund (“Keren Hishtalmut”). The Company
shall contribute to such fund an amount equal to 7.5% (seven percent and one half of one percent) of the Salary, and the Employee
shall contribute to such fund an amount equal to 2.5% (two percent and one half of one percent) of the Salary.

 

    3

     

    

 

9.3 The
Employee’s aforementioned contributions (for the Savings Fund and for Keren Hishtalmut) shall be transferred to the above
referred to plans and funds by the Company by deducting such amounts from each monthly Salary payment. Notwithstanding anything
to the contrary, neither party shall contribute nor shall the Company deduct from each monthly Salary an amount greater than the
maximum amount exempt from tax payment under applicable laws.

 

9.4 Section
14 of the Severance Pay Law. The parties hereby agree and acknowledge that all of the payments that the Company shall make
to the abovementioned managers insurance policy shall be instead of any severance pay to which the Employee or Employee’s
successors shall be entitled to receive from the Company with respect to the salary from which these payments were made and the
period during which they were made. Subject to the Company’s rights according to law in the event of termination for Cause,
in the event of termination of the employer-employee relationship, including resignation, the Employee shall be entitled to receive
a transfer of ownership of the managers insurance plan to the Employee’s name, in the full amount thereof, all in accordance with
Section 14 of the Severance Pay Law 5723-1963. The parties hereby adopt the General Approval of the Minister of Labor and Welfare,
published in the Official Publications Gazette No. 4659 on June 30, 1998, attached hereto as Exhibit C.

 

		10.	Additional Benefits

 

10.1Grant of
Stock Options.On the Effective Date, the Company will grant the Employee options to purchase five percent (5%) of the Company’s
issued and outstanding shares as of the Effective Date, as follows:

 

		·	25% will be fully vested on grant;

 

		·	25% will vest on the consummation of the company’s
planned public offering (the “Public Offering Date”)

 

		·	25% will vest quarterly in the first year following the
Public Offering Date;

 

		·	25% will vest quarterly in the second year following the
Public Offering Date;

 

The exercise
price will equal the fair market value of the shares on the date of grant, which is $0.12 (the closing bid price on the OTC Market
on the date prior to the Effective Date). In the event of a change of control transaction following the Public Offering Date, vesting
will be accelerated, and all of the options will become fully vested. For the avoidance of any doubt, neither the closing of the
second stage of the Amarantus transaction nor the Company’s planned public offering shall be deemed a change of control transaction.

 

10.2Company
Car. At the Employee’s option, the Company shall place at the Employee’s disposal a Company car (the “Car”)
in accordance with the Company’s policies and procedures. The leasing cost of the Car will be borne by the Company, subject
to an Employee contribution of NIS 2,000 per month, to be deducted from the Salary. The Company shall bear all the fixed and variable
costs and expenses of the Car, including registration and license fees, insurance, maintenance and repairs, and fuel, but the Company
shall not bear costs of any tickets, traffic offense or fines of any kind. The Employee will bear all taxes associated with his
use of the Car, which the Company may withhold at source, if applicable. The Employee shall return the Car to the Company in good
working order upon the termination of the Employee’s employment with the Company. For the avoidance of doubt it is hereby clarified
that the Car shall come in lieu of any payment in respect of commuting expenses.

 

    4

     

    

 

10.3Fuel
Costs Reimbursement.If the Employee does not opt to receive a Car, then the Company will reimburse the Employee for all
reasonable fuel costs actually incurred or paid by the Employee for one car owned by the Employee. The Employee shall bear any
and all taxes applicable to him in connection with the reimbursement of fuel costs, if any, which the Company may withhold at source,
if applicable.

 

10.4Cellular
Phone.The Company shall place at the Employee’s disposal a cellular phone (the “Phone”) in accordance
with the Company’s policies and procedures. All expenses incurred in connection with the use and maintenance of the Phone
shall be borne by the Company. The Employee shall bear any and all taxes applicable to him in connection with the Phone and/or
the use thereof, which the Company may withhold at source, if applicable. The Employee shall return the Phone to the Company in
good working order upon the termination of the Employee’s employment with the Company.

 

10.5Laptop
Computer.The Company shall place at the Employee’s disposal a laptop computer (the “Laptop”) in
accordance with the Company’s policies and procedures. The Employee shall bear any and all taxes applicable to him in connection
with the Laptop and/or the use thereof, which the Company may withhold at source, if applicable. The Employee shall return the
Laptop to the Company in good working order upon the termination of the Employee’s employment with the Company.

 

		11.	Vacation.

 

The Employee
shall be entitled to the number of vacation days per year as set forth in Exhibit A. The Employee must use at least
five (5) vacation days each year and the remainder may be accumulated each year for a maximum of two years accrual. Any accrual
in excess of two annual vacation allotments will automatically be voided, and the Employee will not be entitled to redeem these
days for payment.

 

		12.	Sick Leave; Convalescence Pay.

 

The Employee
shall be entitled to that number of days of paid sick leave per year as set forth in Exhibit A (with unused days
to be accumulated in accordance with applicable law), and also to Convalescence Pay (“Dmei Havra’a”) pursuant
to applicable law.

 

		13.	D&O Insurance and Indemnification

 

13.1 The
Company shall include the Employee within the Company’s Directors and Officers Liability Insurance Policy with coverage that is
sufficient to cover the Employee’s activities hereunder.

 

13.2 The
Company shall indemnify the Employee in the event he is a party or is threatened to be made a party to any threatened, pending
or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than action by or in the
right of the Company) by reason of the fact that he is or was a director, officer, employee or agent of the Company, or is or was
serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture,
trust or other enterprise, against expenses (including attorney’s fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner
he reasonably believed to be in or not opposed to the best interest of the Company and, with respect to any criminal action or
proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment,
order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption
that the Employee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests
of the Company, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was unlawful.

 

    5

     

    

 

		14.	Miscellaneous

 

14.1Entire Agreement.This
Agreement, including the exhibits, constitutes the entire understanding and agreement between the parties hereto, and supersedes
any and all prior discussions, agreements and correspondence with regard to the subject matter hereof.

 

14.2Amendments.This
Agreement may not be amended, modified or supplemented in any respect, except by a subsequent writing executed by both parties
hereto.

 

14.3Waiver.No failure,
delay or forbearance of either party in exercising any power or right hereunder shall in any way restrict or diminish such party’s
rights and powers under this Agreement, nor operate as a waiver of any breach or nonperformance by either party of any terms or
conditions hereof.

 

14.4Severability.In
the event it shall be determined under any applicable law that a certain provision set forth in this Agreement is invalid or unenforceable,
such determination shall not affect the remaining provisions of this Agreement unless the business purpose of this Agreement is
substantially frustrated thereby.

 

14.5 Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the state of Israel.

 

IN WITNESS
WHEREOF the parties have signed this Agreement as of the date first hereinabove set forth.

 

	Todos Medical Ltd.	 	Herman Weiss, M.D.
	 	 	 	 	 
	 	 	 
	By:		 	By:	 Herman Weiss, M.D.
	Title:		 	 	

 

    6

     

    

 

Exhibit A

To the Employment Agreement by and between

Todos Medical Ltd. and the Employee

 

	Name of Employee:	 	Herman Weiss, M.D.
	 	 	 
	ID No. of Employee:	 	332266907
	 	 	 
	Address of Employee:	 	11 Rechov Asher, Bet Shemesh
	 	 	 
	Position in the Company:	 	CEO
	 	 	 
	Reporting to:	 	Board of Directors
	 	 	 
	Notice Period:	 	Three (3) Months
	 	 	 
	Salary:	 	NIS 47,840
	 	 	 
	Vacation Days per Year:	 	22 Days
	 	 	 
	Sick Leave Days per Year:	 	In accordance with applicable law
	 	 	 

 

    7

     

    

 

Exhibit B

 

Confidentiality, Inventions Assignment,
and Non-Compete Agreement

(the “Agreement”)

 

I acknowledge that
as a result of my employment, I may develop, receive, or otherwise have access to confidential or proprietary information, which
is of value to Todos Medical Ltd. (together with any parent, affiliate, or subsidiary, the “Company”). I therefore
agree, as a condition of my employment, as follows:

 

		1.	Nondisclosure.

 

1.1 Recognition
of Company’s Rights; Nondisclosure. At all times during my employment with the Company and thereafter, I will hold in strictest
confidence and will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information (defined below), except
as such disclosure, use or publication may be required in connection with my work for the Company, or unless an officer of the
Company expressly authorizes such in writing or unless such information becomes public knowledge. I will obtain the Company’s written
approval before publishing or submitting for publication any material (written, verbal, or otherwise) that relates to my work at
the Company and/or incorporates any Proprietary Information. I hereby assign to the Company, without any further royalty or payment,
any rights I may have or acquire in such Proprietary Information and recognize that all Proprietary Information shall be the sole
property of the Company and its assigns.

 

1.2 Proprietary
Information. The term “Proprietary Information” shall mean any and all confidential and/or proprietary knowledge,
data or information of the Company. By way of illustration but not limitation, “Proprietary Information” includes (a) trade
secrets, inventions, mask works, ideas, processes, formulas, source and object codes, data, lists, programs, other works of authorship,
know-how, improvements, discoveries, developments, designs and techniques (hereinafter collectively referred to as “Inventions”);
and (b) information regarding plans for research, development, new products, marketing and selling, business plans, budgets
and unpublished financial statements, licenses, prices and costs, suppliers and customers; and (c) information regarding the skills
and compensation of other employees of the Company. Notwithstanding the foregoing, it is understood that, at all such times, I
am free to use information which is generally known in the trade or industry, which is not gained as result of a breach of this
Agreement, to whatever extent and in whichever way I wish.

 

1.3 Third
Party Information. I understand, in addition, that the Company has received, and in the future will receive, from third parties
confidential or proprietary information (“Third Party Information”) subject to a duty on the Company’s part to maintain
the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment and thereafter,
I will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than Company personnel who
need to know such information in connection with their work for the Company) or use, except in connection with my work for the
Company, Third Party Information unless expressly authorized by an officer of the Company in writing.

 

1.4 No
Improper Use of Information of Prior Employers and Others. During my employment by the Company, I will not improperly use or
disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation
of confidentiality, and I will not bring onto the premises of the Company any unpublished documents or any property belonging to
any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that
former employer or person.

 

1.5 No
Expectation of Privacy. I recognize and agree that I have no expectation of privacy with respect to the Company’s telecommunications,
networking, or information processing systems (including, without limitation, stored computer files, email messages and voice messages)
and that my activity, and any files or messages, on or using any of those systems may be monitored at any time without notice.

 

    8

     

    

 

		2.	Assignment of Inventions.

 

2.1 Proprietary
Rights. The term “Proprietary Rights” shall mean:

 

(i) patents,
whether in the form of utility patents or design patents and all pending applications for such patents;

 

(ii) trademarks,
trade names, service marks, designs, logos, trade dress, and trade styles, whether or not registered, and all pending applications
for registration of the same;

 

(iii) copyrights
or copyrightable material, including but not limited to books, articles and publications, whether or not registered, and all pending
applications for registration of the same;

 

(iv) inventions,
research records, trade secrets, confidential information, product designs, engineering specifications and drawings, technical
information, formulae, customer lists, supplier lists and market analyses;

 

(v) computer
programs, including, without limitation, computer programs embodied in semiconductor chips or otherwise embodied, and related flow-charts,
programmer notes, updates and data, whether in object or source code form; and

 

		(vi)	all other intellectual property rights throughout the world.

 

2.2Assignment
of Inventions. I hereby assign and agree to assign in the future (when any such Inventions or Proprietary Rights are first
reduced to practice or first fixed in a tangible medium, as applicable) to the Company all my right, title and interest in and
to any and all Inventions (and all Proprietary Rights with respect thereto) whether or not patentable or registrable under copyright
or similar statutes, made or developed, or conceived or reduced to practice or learned by me, either alone or jointly with others,
during the period of my employment with the Company (i) which relate to the Company’s Entities’ business or actual
or demonstrably anticipated research or development, (ii) which are developed in whole or in part on the Company’s time or with
the use of any of the Company’s equipment, supplies, facilities or trade secret information, or (iii) which result directly or
indirectly from any work I performed for the Company (each a “Company Invention”). I agree to assign and do hereby
assign to the Company or its designee(s) all my right, title and interest worldwide in such Company Inventions and in all intellectual
property rights based upon such Inventions. Without limitation of any of the other provisions of this agreement, I irrevocably
confirm that the consideration explicitly set forth in my employment agreement is in lieu of any rights for compensation that may
arise in connection with the Company Inventions under applicable law and waive any right to claim royalties or other consideration
with respect to any Company Invention, including under Section 134 of the Israeli Patent Law – 1967, and hereby waive any
rights I may have with respect thereto.

 

2.3Government
or Third Party. I also agree to assign all my right, title and interest in and to any particular Company Invention to any third
party, including without limitation government agency, as directed by the Company.

 

2.4Works for
Hire. I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope
of my employment and which are protectable by copyright are the property of the Company pursuant to applicable copyright law.

 

2.5 Assignment
or Waiver of Moral Rights. Any assignment of copyright hereunder (and any ownership of a copyright as a work made for hire)
includes all rights of paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to
as “moral rights” (collectively “Moral Rights”). To the extent such Moral Rights cannot be assigned under
applicable law and to the extent the following is allowed by the laws in the various countries where Moral Rights exist, I hereby
waive such Moral Rights and consent to any action of the Company that would violate such Moral Rights in the absence of such consent.

 

    9

     

    

 

2.6
Enforcement of Proprietary Rights.

 

2.6.1 I
will assist the Company in every proper way to obtain, and from time to time enforce, any Proprietary Rights relating to Company
Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts
(including appearances as a witness) as the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing,
sustaining and enforcing such Proprietary Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments
of such Proprietary Rights to the Company or its designee. My obligation to assist the Company with respect to Proprietary Rights
relating to such Company Inventions in any and all countries shall continue indefinitely beyond the termination of my employment,
but the Company shall compensate me at a reasonable rate after my termination for the time actually spent by me at the Company’s
request on such assistance.

 

2.6.2 In
the event the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection
with the actions specified in the preceding paragraph, I hereby irrevocably designate and appoint the Company and its duly authorized
officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf
to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding
paragraph with the same legal force and effect as if executed by me. I hereby waive and quit claim to the Company any and all claims,
of any nature whatsoever, which I now or may hereafter have for infringement of any Proprietary Rights assigned hereunder to the
Company.

 

		3.	Records.

 

I agree to keep and
maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that may be required by the
Company) of all Proprietary Information developed by me and all Inventions made by me during the period of my employment at the
Company, which records shall be available to and remain the sole property of the Company at all times.

 

		4.	Competitive Activities.

 

During the term of
this Agreement and for a period of six (6) months from the effective date of termination of this Agreement for any reason (“the
Termination Date”), I will not directly or indirectly:

 

(i) carry
on or hold an interest in any company, venture, entity or other business (other than a minority interest in a publicly traded company)
which directly competes with the products or services, or demonstrably anticipated future products or services, of the Company,
(“a Competing Business”) (including, without limitation, as a shareholder);

 

(ii) act
as a consultant or employee or officer or in any managerial capacity in a Competing Business or supply in direct competition with
the Company restricted services to any person who, to my knowledge, was provided with services by the Company any time during the
twelve (12) months immediately prior to the Termination Date;

 

(iii) solicit,
canvass or approach or endeavor to solicit, canvass or approach any person who, to my knowledge, was provided with services by
the Company at any time during the twelve (12) months immediately prior to the Termination Date, for the purpose of offering services
or products which directly compete with the services or products supplied by the Company at the Termination Date; or

 

    10

     

    

 

(iv) employ,
solicit or entice away or endeavor to solicit or entice away from the Company any person employed by the Company any time during
the twelve (12) months immediately prior the Termination Date with a view to inducing that person to leave such employment and
to act for another employer in the same or a similar capacity.

 

4.2 I
acknowledge that my Salary includes a payment to me for my undertaking the non-competition obligations set forth in this Section
4. Without limitation of any of the other provisions of this Agreement, I irrevocably confirm that the consideration explicitly
set forth in my employment agreement is in lieu of any rights for additional compensation that may arise in connection with my
non-competition obligations.

 

		5.	No Conflicting Obligation.

 

I represent
that my performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement
to keep in confidence information acquired by me in confidence or in trust prior to my employment by the Company. I have not entered
into, and I agree I will not enter into, any agreement either written or oral in conflict herewith.

 

		6.	Return of Company Documents.

 

When I
leave the employ of the Company, I will deliver to the Company any and all drawings, notes, memoranda, specifications, devices,
formulas, and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions,
Third Party Information or Proprietary Information of the Company.

 

		7.	Notification of New Employer.

 

In the
event that I leave the employ of the Company, I hereby consent to the notification of my new employer of my rights and obligations
under this Agreement.

 

		8.	General Provisions.

 

8.1 Severability.
In case any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of
this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been
contained herein. If moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to
be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing
it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.

 

8.2 Successors
and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives and will
be for the benefit of the Company, its successors, and its assigns.

 

8.3 Survival.
The provisions of this Agreement shall survive the termination of my employment and the assignment of this Agreement by the Company
to any successor in interest or other assignee; provided, however, that the provisions of Section 4 of this Agreement shall remain
in full force and effect only for the period of time detailed therein.

 

8.4 Waiver.
No waiver by the Company of any breach of this Agreement shall be a waiver of any preceding or succeeding breach. No waiver by
the Company of any right under this Agreement shall be construed as a waiver of any other right. The Company shall not be required
to give notice to enforce strict adherence to all terms of this Agreement.

 

    11

     

    

 

8.5  
 Assignment. This Agreement may be assigned by the Company. I may not assign or delegate my duties under this
Agreement without the Company’s prior written approval.

 

8.6  Entire
Agreement. The obligations pursuant to Sections 1, 2 and 4 of this Agreement shall apply to any time during which I was previously
employed, or am in the future employed, by the Company as a consultant if no other agreement governs nondisclosure and assignment
of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties with respect to
the subject matter hereof and supersedes and merges all prior discussions or agreements between us with respect to the subject
matter hereof. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective
unless in writing and signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation
will not affect the validity or scope of this Agreement.

 

8.7  Injunction.
I agree that it would be difficult to measure damage to the Company from any breach of mine of the promises set forth in Sections
1, 2, 3 and 4 hereof, and that injury to the Company from any such breach would be impossible to calculate, and that money damages
would therefore be an inadequate remedy for any such breach. Accordingly, I agree that if I breach any provision of Sections 1,
2, 3 and 4 hereof, the Company will be entitled, in addition to all other remedies it may have, to an injunction or other appropriate
orders to restrain any such breach by me without showing or proving any actual damage sustained by the Company.

 

8.8  Governing
Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Israel, without giving
effect to the rules respecting conflict-of-law.

 

I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND
ITS TERMS.

 

	 	 
	Name:	Herman Weiss

                                             
	
	Date: 	__________________	 

 

    12

     

    

 

 

 

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]